Invion and Hanlim Secure $2M Boost for Oesophageal Cancer Therapy Trials

• Up to A$2 million non-dilutive funding secured from Hanlim and South Korean government
• Two-stage preclinical program targeting oesophageal cancer with HL270 (INV043)
• Stage 1 focuses on efficacy in animal models including combination with immune checkpoint inhibitors
• Stage 2 aims for regulatory approval and preparation for first-in-human clinical trial in Australia